Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 89-90, Issue , 2004, Pages 239-244

  White, John H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

1 ,25 Dihydroxyvitamin D3; Cancer chemoprevention; Gene expression profiling; Genomics; Immune system; Microarray; Vitamin D receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CALCITRIOL DERIVATIVE; IMMUNOMODULATING AGENT; SEOCALCITOL; VITAMIN D RECEPTOR;

CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CANCER; CONFERENCE PAPER; DNA MICROARRAY; DRUG ACTIVITY; DRUG POTENCY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GENETIC ANALYSIS; GENOME; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION;

CALCITRIOL; GENE EXPRESSION PROFILING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 3042645085     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.03.074     Document Type: Conference Paper

References (50)

1. Holick M.F. Sunlight "D"ilemma: risk of skin cancer or bone disease and muscle weakness. Lancet. 357:2001;4-6
2. Slominski A., Wortsman J. Neuroendocrinology of the skin. Endocrine Rev. 21:2000;457-487
3. Jones G., Strugnell S.A., DeLuca H. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 78:1998;1193-1231
4. Okuda K., Usui E., Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. J. Lipid Res. 36:1995;1641-1652
5. 3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem. J. 262:1989;173-180
6. Baker A.R., McDonnell D.P., Hughes M., Crisp T.M., Mangelsdorf D.J., Haussler M.R., Pike J.W., Shine J., O'Malley B.W. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. U.S.A. 85:1988;3294-3298
7. Aranda A., Pascual A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81:2001;1269-1304
8. 3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of VDR-RXR heterodimer-mediated transactivation. Mol. Cell Biol. 15:1995;1154-1161
9. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., Ishizuka H., Kharasch E., Schuetz J., Schuetz E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha, 25-dihydroxyvitamin D3. Mol. Pharmacol. 60:2001;1399-1406
10. Drocourt L., Ourlin J.C., Pascussi J.M., Maurel P., Vilarem M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 277:2002;25125-25132
11. Thompson P.D., Jurutka P.W., Whitfield G.K., Myskowski S.M., Eichhorst K.R., Dominguez C.E., Haussler C.A., Haussler M.R. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem. Biophys. Res. Comm. 299:2002;730-738
12. McKenna N.J., O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 108:2002;465-474
13. Rachez C., Freedman L.P. Mechanisms of gene regulation by vitamin D-3 receptor: a network of coactivator interactions. Gene. 246:2000;9-21
14. Guyton K.Z., Kensler T.W., Posner G.H. Cancer chemoprevention using natural vitamin D and synthetic analogs. Ann. Rev. Pharmacol. Toxicol. 41:2001;421-442
15. O'Kelly J., Hisatake J., Hisatake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J. Clin. Invest. 109:2002;1091-1099
16. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., Goltzman D. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7498-7503
17. Penna G., Adorini L. 1, 25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164:2000;2405-2411
18. Griffin M.D., Lutz W.H., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1, 25-dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98:2001;680-705
19. Canning M.O., Grotenhuis K., de Wit H., Ruwhof C., Drexhage H.A. 1-alpha, 25-Dihydroxyvitamin D3 (1, 25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. 145:2001;351-357
20. Lippman S.M., Benner S.E., Hong W.K. Cancer chemoprevention. J. Clin. Oncol. 12:1994;851-873
21. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev. 16:1995;200-257
22. Mork Hansen C., Hamberg K.J., Binderup E., Binderup E. Seocalcitol (EB 1089) A vitamin D analog of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharmaceut. Des. 6:2000;803-828
23. Prudencio J., Akutsu N., Wong T., Bastien Y., Lin R., Black M.J., Alaoui-Jamali M., White J.H. Action of low calcemic 1, 25-dihydroxyvitamin D3 analog EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 93:2001;745-753
24. 3 and its analog EB1089 under growth inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15:2001;1127-1139
25. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., Sotiropoulou G., Diamandis E.P., Hudson T.J., White J.H. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 signaling on cell proliferation. Mol. Endocrinol. 16:2002;1243-1256
26. Hu L., Crowe D.L., Rheinwald J.G., Chambon P., Gudas L.J. Abnormal expression of retinoid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma lines. Cancer Res. 51:1991;3972-3981
27. Zou A., Elgort M.G., Allegretto E.A. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1, 25-dihydroxyvitamin D3. J. Biol. Chem. 272:1997;19027-19034
28. Crawford H.C., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res. 58:1998;5206-5215
29. Kissmeyer A.M., Binderup E., Binderup L., Hansen C.M., Andersen N.R., Makin H.L.J., Schroeder N.J., Shankar V.N., Jones G. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol. 53:1997;1087-1097
30. 3: implications of cell growth and signaling. Endocrine Rev. 23:2002;763-786
31. Akutsu N., Bastien Y., Lin R., Mader S., White J.H. Amphiregulin is a vitamin D target gene in squamous cell and breast carcinoma. Biochem. Biophys. Res. Commun. 281:2001;1051-1056
32. Liu M., Lee M.-H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 10:1996;142-153
33. Munker R., Kobayashi T., Elstner E., Norman A.W., Uskokovic M., Zhang W., Andreeff M., Koeffler H.P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation and induction of WAF1 in myeloid leukemia. Blood. 88:1996;2201-2209
34. KIP1 in vitamin D analogue-treated cancer cells. Endocrinology. 144:2003;749-753
35. Liu Z.Y., Ganju R.K., Wang G.F., Ona M.A., Hatch W.C., Zheng T., Avraham S., Gill P., Groopman J.E. Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells. J. Clin. Invest. 99:1997;1798-1804
36. Sampath D., Winneker R.C., Zhang Z.M. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17 beta-estradiol and overexpression in human breast cancer. Endocrinology. 142:2001;2540-2548
37. Ikematsu S., Yano A., Aridome K., Kikuchi M., Kumai H., Nagano H., Okamoto K., Oda M., Sakuma S., Aikou T., Muramatsu H., Kadomatsu K., Muramatsu T. Serum midkine levels are increased in patients with various types of carcinomas. Brit. J. Cancer. 83:2000;701-706
38. Suminami Y., Nagashima S., Murakami A., Nawata S., Gondo T., Hirakawa H., Numa F., Silverman G.A., Kato H. Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res. 61:2001;1776-1780
39. Tomita K., van Bokhoven A., van Leenders G.J.L.H., Ruijter E.T.G., Jansen C.F.J., Bussmakers M.J.G., Schalken J.A. Cadherin switching in human prostate cancer progression. Cancer Res. 60:2000;3650-3654
40. Kudo Y., Kitajima S., Sato S., Miyauchi M., Ogawa I., Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61:2001;7044-7047
41. Galbiati F., Polastri L., Thorens B., Dupraz P., Fiorina P., Cavallaro U., Christofori G., Davalli A.M. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology. 144:2002;1832-1841
42. Hollander M.C., Sheikh M.S., Bulavin D.V., Lundgren K., Augeri-Henmueller L., Shehee R., Molinaro T.A., Kim K.E., Tolosa E., Ashwell J.D., Rosenberg M.P., Zhan Q., Fernandez-Salguero P.M., Morgan W.F., Deng C.X., Fornace A.J. Jr. Genomic instability in Gadd45α-deficient mice. Nat. Genet. 23:1999;176-184
43. Krishnan A.V., Peehl D.M., Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell Biochem. 88:2003;363-371
44. Swami S., Raghavachari N., Muller U.R., Bao Y.P., Feldman D. Breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res. Treat. 80:2003;49-62
45. Danilenko M., Wang Q., Wang X.N., Levy J., Sharoni Y., Studzinski G.P. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1 alpha 25-dihydroxyvitamin D-3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res. 63:2003;1325-1332
46. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., Kensler T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98:2001;3410-3415
47. Wang X.N., Gardner J.P., Kheir A., Uskokovic M.R., Studzinski G.P. Synergistic induction of HL60 cell differentiation by ketoconazole and 1-desoxy analogues of vitamin D-3. J. Natl. Cancer Inst. 89:1997;1199-1206
48. Townsend M.J., Fallon P.G., Matthews D.J., Jolin H.E., McKenzie A.N.J. T1/ST2-, mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191:2000;1069-1075
49. Cantorna M.T., Hayes C.E., DeLuca H.F. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 93:1996;7861-7864
50. Mason J., Mason A.R., Cork M.J. Topical preparations for the treatment of psoriasis: a systematic review. Br. J. Dermatol. 146:2002;351-364